A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. / Senkowski, Wojciech; Gall-Mas, Laura; Falco, Matías Marín; Li, Yilin; Lavikka, Kari; Kriegbaum, Mette C.; Oikkonen, Jaana; Bulanova, Daria; Pietras, Elin J.; Voßgröne, Karolin; Chen, Yan Jun; Erkan, Erdogan Pekcan; Dai, Jun; Lundgren, Anastasia; Grønning Høg, Mia Kristine; Larsen, Ida Marie; Lamminen, Tarja; Kaipio, Katja; Huvila, Jutta; Virtanen, Anni; Engelholm, Lars; Christiansen, Pernille; Santoni-Rugiu, Eric; Huhtinen, Kaisa; Carpén, Olli; Hynninen, Johanna; Hautaniemi, Sampsa; Vähärautio, Anna; Wennerberg, Krister.
In: Developmental Cell, Vol. 58, No. 12, 2023, p. 1106-1121.e7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
AU - Senkowski, Wojciech
AU - Gall-Mas, Laura
AU - Falco, Matías Marín
AU - Li, Yilin
AU - Lavikka, Kari
AU - Kriegbaum, Mette C.
AU - Oikkonen, Jaana
AU - Bulanova, Daria
AU - Pietras, Elin J.
AU - Voßgröne, Karolin
AU - Chen, Yan Jun
AU - Erkan, Erdogan Pekcan
AU - Dai, Jun
AU - Lundgren, Anastasia
AU - Grønning Høg, Mia Kristine
AU - Larsen, Ida Marie
AU - Lamminen, Tarja
AU - Kaipio, Katja
AU - Huvila, Jutta
AU - Virtanen, Anni
AU - Engelholm, Lars
AU - Christiansen, Pernille
AU - Santoni-Rugiu, Eric
AU - Huhtinen, Kaisa
AU - Carpén, Olli
AU - Hynninen, Johanna
AU - Hautaniemi, Sampsa
AU - Vähärautio, Anna
AU - Wennerberg, Krister
N1 - Publisher Copyright: © 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.
AB - The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.
KW - 3D cell culture, culture conditions
KW - functional precision medicine
KW - high-grade serous ovarian cancer
KW - HPLM
KW - organoid biobank
KW - organoids
KW - personalized medicine
KW - scRNA-seq
KW - tumor models
U2 - 10.1016/j.devcel.2023.04.012
DO - 10.1016/j.devcel.2023.04.012
M3 - Journal article
C2 - 37148882
AN - SCOPUS:85161580449
VL - 58
SP - 1106-1121.e7
JO - Developmental Cell
JF - Developmental Cell
SN - 1534-5807
IS - 12
ER -
ID: 360976198